GRAIL公司在2026年美国临床肿瘤学会(ASCO)年会上,公布了其Pathfinder 2研究的突破性成果。这项涉及超过35,000名参与者的研究显示,其开发的Galleri®多癌种早期检测技术,能够显著提高癌症检出率,同时展现出稳健的性能表现和良好的安全性特征。
GRAIL公司在2026年美国临床肿瘤学会(ASCO)年会上,公布了其Pathfinder 2研究的突破性成果。这项涉及超过35,000名参与者的研究显示,其开发的Galleri®多癌种早期检测技术,能够显著提高癌症检出率,同时展现出稳健的性能表现和良好的安全性特征。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.